The estimated Net Worth of Lauren Mastrocola is at least $1.82 Million dollars as of 16 June 2022. Lauren Mastrocola owns over 3,000 units of Praxis Precision Medicines stock worth over $1,818,795 and over the last 4 years he sold PRAX stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Lauren Mastrocola PRAX stock SEC Form 4 insiders trading
Lauren has made over 2 trades of the Praxis Precision Medicines stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of PRAX stock worth $5,790 on 16 June 2022.
The largest trade he's ever made was exercising 12,218 units of Praxis Precision Medicines stock on 2 November 2020 worth over $40,319. On average, Lauren trades about 1,015 units every 39 days since 2020. As of 16 June 2022 he still owns at least 31,391 units of Praxis Precision Medicines stock.
You can see the complete history of Lauren Mastrocola stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lauren Mastrocola biography
Lauren Mastrocola is the VP of Fin. & Principal Accounting Officer at Praxis Precision Medicines.
What's Lauren Mastrocola's mailing address?
Lauren's mailing address filed with the SEC is C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110.
Insiders trading at Praxis Precision Medicines
Over the last 4 years, insiders at Praxis Precision Medicines have traded over $16,246,895 worth of Praxis Precision Medicines stock and bought 242,294 units worth $603,092 . The most active insiders traders include Holdings A/S Novo, Parallel Master Fund L.P.Bl..., and Dean J Mitchell. On average, Praxis Precision Medicines executives and independent directors trade stock every 48 days with the average trade being worth of $3,178,530. The most recent stock trade was executed by Jill De Simone on 5 October 2023, trading 14,500 units of PRAX stock currently worth $25,375.
What does Praxis Precision Medicines do?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
What does Praxis Precision Medicines's logo look like?
Complete history of Lauren Mastrocola stock trades at Praxis Precision Medicines
Praxis Precision Medicines executives and stock owners
Praxis Precision Medicines executives and other stock owners filed with the SEC include:
-
Marcio Souza M.B.A.,
Pres, CEO & Director -
Dr. Bernard Ravina,
Chief Medical Officer -
Nicole Sweeny,
Chief Commercial Officer -
Alex Kane,
VP of Investor Relations & Corp. Communications -
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.,
Co-Founder & Chief Scientific Officer -
Karl Hansen,
Sr. VP of CMC -
Kelly McCue,
Chief People Officer -
Alex Nemiroff J.D.,
Gen. Counsel & Sec. -
Lauren Mastrocola,
VP of Fin. & Principal Accounting Officer -
Timothy Edwin Kelly,
CFO & Treasurer -
Dr. Steven Petrou,
Co-Founder & Chief Scientific Officer -
Dr. David B. Goldstein Ph.D.,
Co-Founder -
Stefan Vitorovic,
Director -
Jeffrey Chodakewitz,
Director -
Lifesciences Iii, L.P.Claru...,
-
Gregory Norden,
Director -
William D Young,
Director -
Dean J Mitchell,
Director -
Parallel Master Fund L.P.Bl...,
-
Jill De Simone,
Director -
Alex Nemiroff,
General Counsel and Secretary -
Nicole Sweeny,
Chief Commercial Officer -
Holdings A/S Novo,
10% owner -
Bernard Ravina,
Chief Medical Officer -
Merit Ester Cudkowicz,
Director -
Lifesciences Iii, L.P.Claru...,
-
Timothy Edwin Kelly,
Chief Financial Officer -
Parallel Master Fund L.P.Bl...,
-
Marcio Souza,
Chief Executive Officer